AvPAK
PANTOPRAZOLE SODIUM- pantoprazole sodium tablet, delayed release
AvPAK
1 INDICATIONS AND USAGE
Pantoprazole Sodium Delayed-Release Tablets, USP are indicated for:
1.1 Short-Term Treatment of Erosive Esophagitis Associated With Gastroesophageal Reflux Disease (GERD)
Pantoprazole is indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis (EE). For those adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of Pantoprazole may be considered. Safety of treatment beyond 8 weeks in pediatric patients has not been established.
1.2 Maintenance of Healing of Erosive Esophagitis
Pantoprazole is indicated for maintenance of healing of EE and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with GERD. Controlled studies did not extend beyond 12 months.
1.3 Pathological Hypersecretory Conditions Including Zollinger-Ellison (ZE) Syndrome
Pantoprazole is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison (ZE) Syndrome.
2 DOSAGE AND ADMINISTRATION
2.1 Recommended Dosing Schedule
Pantoprazole is supplied as delayed-release tablets. The recommended dosages are outlined in Table 1.
| Indication | Dose | Frequency |
|---|---|---|
| ||
| Short-Term Treatment of Erosive Esophagitis Associated With GERD | ||
| Adults | 40 mg | Once daily for up to 8 weeks * |
| Children (5 years and older) | ||
| ≥ 15 kg to < 40 kg | 20 mg | Once daily for up to 8 weeks |
| ≥ 40 kg | 40 mg | |
| Maintenance of Healing of Erosive Esophagitis | ||
| Adults | 40 mg | Once daily † |
| Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome | ||
| Adults | 40 mg | Twice daily ‡ |
2.2 Administration Instructions
Directions for method of administration for each dosage form are presented in Table 2.
| Formulation | Route | Instructions * |
|---|---|---|
| ||
| Delayed-Release Tablets | Oral | Swallowed whole, with or without food |
Take a missed dose as soon as possible. If it is almost time for the next dose, skip the missed dose and take the next dose at the regular scheduled time. Do not take 2 doses at the same time.
Pantoprazole Sodium Delayed-Release Tablets
Swallow Pantoprazole Sodium Delayed-Release Tablets whole, with or without food in the stomach. For patients unable to swallow a 40 mg tablet, two 20 mg tablets may be taken. Concomitant administration of antacids does not affect the absorption of Pantoprazole Sodium Delayed-Release Tablets.
3 DOSAGE FORMS AND STRENGTHS
Delayed-Release Tablets:
- 40 mg, white to off-white, oval-shaped coated tablet, debossed with “17” on one side
- 20 mg, white to off-white, oval-shaped coated tablet, imprinted in black with “18” on one side
4 CONTRAINDICATIONS
-
Pantoprazole is contraindicated in patients with known hypersensitivity to any component of the formulation or any substituted benzimidazole. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria [see Warnings and Precautions ( 5.2), Adverse Reactions ( 6)] .
-
Proton pump inhibitors (PPIs), including Pantoprazole, are contraindicated in patients receiving rilpivirine-containing products [see Drug Interactions ( 7)] .
5 WARNINGS AND PRECAUTIONS
5.1 Presence of Gastric Malignancy
In adults, symptomatic response to therapy with Pantoprazole does not preclude the presence of gastric malignancy. Consider additional follow-up and diagnostic testing in adult patients who have a suboptimal response or an early symptomatic relapse after completing treatment with a PPI. In older patients, also consider an endoscopy.
5.2 Acute Tubulointerstitial Nephritis
Acute tubulointerstitial nephritis (TIN) has been observed in patients taking PPIs and may occur at any point during PPI therapy. Patients may present with varying signs and symptoms from symptomatic hypersensitivity reactions to non-specific symptoms of decreased renal function (e.g., malaise, nausea, anorexia). In reported case series, some patients were diagnosed on biopsy and in the absence of extra-renal manifestations (e.g., fever, rash or arthralgia). Discontinue Pantoprazole and evaluate patients with suspected acute TIN [see Contraindications ( 4)] .
5.3 Clostridium difficile -Associated Diarrhea
Published observational studies suggest that PPI therapy like Pantoprazole may be associated with an increased risk of Clostridium difficile associated diarrhea, especially in hospitalized patients. This diagnosis should be considered for diarrhea that does not improve [see Adverse Reactions ( 6.2)] .
Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.
https://medlibrary.org/lib/rx/meds/pantoprazole-sodium-59/
